October 29, 2024
A new consensus statement from the American Diabetes Association provides advice on the use of continuous glucose monitoring (CGM) systems in hospital settings, based in part […]
October 29, 2024
TOPLINE: Opioid use has multiple negative effects on the endocrine system and can lead to reproductive, bone, and adrenal hormone health complications, reported a scientific statement. […]
October 29, 2024
SAN ANTONIO — The upcoming Obesity Week meeting will feature new clinical trial data for glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs, along with deep […]
October 28, 2024
The US Food and Drug Administration (FDA) has notified compounding pharmacies that the agency — at least temporarily — won’t take action against them for creating […]
October 28, 2024
The potential of glucagon-like peptide 1 (GLP-1) receptor agonists continues to grow more promising as new studies identify benefits beyond glucose control and weight loss. With […]
October 25, 2024
The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals to warn patients about common and serious side effects associated with glucagon-like peptide-1 receptor […]
October 25, 2024
TOPLINE: High-intensity exercise suppresses ghrelin levels more than moderate-intensity exercise, leading to a greater reduction in hunger. This effect may be more pronounced in women than […]
October 24, 2024
TOPLINE: Increases in prescriptions for both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors were observed in patients with type 1 […]
October 24, 2024
TOPLINE: A 48-week oral semaglutide treatment regimen for type 2 diabetes (T2D) reduces weight and improves liver steatosis, liver stiffness, and liver enzyme levels in patients […]